Only line in the announcement potentially relating to potency assays is the last bit in my opinion - "...seeking to address all remaining product characterization issues".
Potency assay stuff is product characterization stuff - so that could be an acknowledgement (in an obscure general way - that they don't have an all clear on potency assay approach) but as I said "product characterization" is a broader term. It could pick up screening product for viral contamination etc and a bunch of other stuff unrelated to potency assays (as specific metrics intended to track product potency).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-306
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.015(1.41%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.09 | $1.05 | $4.232M | 3.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 61694 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.06 | 45910 | 3 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.06 |
Change
-0.015 ( 0.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.09 | $1.05 | 969435 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| MSB (ASX) Chart |